Inquiry backs expansion of GLP-1 RA eligibility

Government urged to make Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) available to more patients  Steps to improve access to GLP-1 RAs for high-risk patients are among 23 recommendations in the Parliamentary Standing Committee on Health, Aged Care and Sport’s inquiry into diabetes.   The committee noted that GLP-1 RAs, including semaglutide (Ozempic) and dulaglutide (Trulicity),